| ProtaGene–Ampersand: investment, 202201 existent portfolio company after merger/acquisition of PPS GmbH + BioAnalytix + GeneWerk GmbH in 7/21 |
2022-01-12 |
| Rockefeller Univ–Lumicks: microscope, 202201 supply of Quadrupole C-Trap system to lab of Prof Michael O’Donnell |
2022-01-12 |
| Scitara–Flybridge Capital: investment, 202201 financing round Series B totalling $15m incl existing + co-investor Flybridge Capital |
2022-01-11 |
| Scitara–Northpond Ventures: investment, 202201 financing round Series B totalling $15m incl existing + lead investor Northpond Ventures |
2022-01-11 |
| Scitara–Scott Partnership: public relations, 202201 service existent by Scott PR |
2022-01-11 |
| Scitara–SEVERAL: investment, 202201 financing round Series B $15m led by Northpond Ventures |
2022-01-11 |
| Exelead–Merck (DE): investment, 202201– acquisition $760m in cash by Merck ANNOUNCED |
2022-01-06 |
| BioNTech–Pfizer: investment, 202201 equitiy investment $150m by Pfizer in connection with shingles vaccine collaboration |
2022-01-05 |
| Pfizer–BioNTech: mRNA-based vaccines, 202201– collab developm $50m net cash upfront shingles vaccine with shared development cost + profits |
2022-01-05 |
| PhoreMost–Polaris Quantum Biotech: cancer drug discovery, 202201– collab r+d using Tachyon quantum computing platform with Siteseeker platform |
2022-01-05 |
| Sound Bioventures–Denmark (govt): investment, 202201 1st closing of 1st fund totalling €110m incl investor Vćkstfonden |
2022-01-04 |
| Sound Bioventures–EU (govt): investment, 202201 1st closing of 1st fund totalling €110m incl investor EIF unde EGF |
2022-01-04 |
| Sound Bioventures–Novo Group: investment, 202201 1st closing of 1st fund totalling €110m incl investor Novo Holdings |
2022-01-04 |
| Sound Bioventures–PERSON: investment, 202201 1st closing of 1st fund totalling €110m incl founding partners C Breum + J Kördel + B Mukhopadhyay |
2022-01-04 |
| Sound Bioventures–Ramsbury Invest: investment, 202201 1st closing of 1st fund totalling €110m incl investor Ramsbury Invest |
2022-01-04 |
| Sound Bioventures–SEVERAL: investment, 202201 first closing of €110m Sound Bioventures Fund I AB |
2022-01-04 |
| Sound Bioventures–Sweden (govt): investment, 202201 1st closing of 1st fund totalling €110m incl investor Saminvest |
2022-01-04 |
| Ortho Clinical Diagnostics–Quidel: investment, 202112– acquisition merger $1.75b in cash + $4.25b in shares results in 38% onwership for Ortho owners |
2021-12-23 |
| Personal Genome Diagnostics–LabCorp: investment, 202112– acquisiton of PGDx for $450m cash at closing + $125m milestones ANNOUNCED |
2021-12-23 |
| Sorriso Pharmaceuticals–Arix Bioscience: investment, 202112 financing round Series A totalling $31m incl $13m (26%stake) from co-lead investor Arix |
2021-12-22 |
| Sorriso Pharmaceuticals–New Enterprise Associates: investment, 202112 financing round Series A totalling $31m incl co-lead investor NEA |
2021-12-22 |
| Sorriso Pharmaceuticals–SEVERAL: investment, 202112 financing round Series A $31m co-led by NEA + Arix Bioscience plc |
2021-12-22 |
| Amunix Pharmaceuticals–Sanofi: investment, 202112– acquisition $1b upfront + $225m milestones ANNOUNCED |
2021-12-21 |
| Protein Metrics–Insightful Science: investment, 202112 acquisition of Protein Metrics by Insightful Science |
2021-12-21 |
| Chord Therapeutics–Merck (DE): investment, 202112– acquisition of Chord by Merck KGaA from sole investor Omega Funds |
2021-12-20 |
| Genenta Science–LifeSci: public relations, 202112 service existent IR by LifeSci Advisors |
2021-12-17 |
| Genenta Science–SEVERAL: investment, 202112 direct offering $8.28m of 720.1k ordinary shares for subscription by exisiting shareholders at $11.5/share |
2021-12-17 |
| NorthSea Therapeutics–Hercules Capital: investment, 202112 financing round Series C totalling $80m incl new + co-investor Hercules Capital |
2021-12-17 |
| NorthSea Therapeutics–New Science Ventures: investment, 202112 financing round Series C totalling $80m incl existing + co-investor New Science |
2021-12-17 |
| NorthSea Therapeutics–OTHER: investment, 202112 financing round Series C totalling $80m incl new + co-investor large managed care organisation |
2021-12-17 |
| NorthSea Therapeutics–SEVERAL: investment, 202112 financing round Series C $80m co-led by Ysios Capital + Forbion Growth |
2021-12-17 |
| NorthSea Therapeutics–Sofinnova: investment, 202112 financing round Series C totalling $80m incl existing + co-investor Sofinnova |
2021-12-17 |
| NorthSea Therapeutics–VenBio: investment, 202112 financing round Series C totalling $80m incl existing + co-investor VenBio |
2021-12-17 |
| Anaveon–Cowen: investment, 202112 financing round Series B totalling CHF110m incl new + co-investor Cowen Healthcare Investments |
2021-12-16 |
| Anaveon–Pfizer: investment, 202112 financing round Series B totalling CHF110m incl new + co-investor Pifzer Ventures |
2021-12-16 |
| Anaveon–Pontifax: investment, 202112 financing round Series B totalling CHF110m incl new + co-investor Pontifax |
2021-12-16 |
| Anaveon–SEVERAL: investment, 202112 financing round Series B CHF110m with new + lead investor Forbion |
2021-12-16 |
| Argobio–GeneCode: GDNF mimetics, 202112– collab development with up to €3m funding for incubation phase by Argobio to incorporate new biotech company |
2021-12-16 |
| Biosero–Bico: investment, 202112– acquisition up to $165m in cash + shares by Bico |
2021-12-16 |
| Evotec–Gates Foundation: grant, 202112– grant $18m for drug r+d in area of women’s health + contraceptive technology |
2021-12-16 |
| Depixus–Casdin Capital: investment, 202112 financing round Series A totalling €30.6m incl new + co-investor Casdin Capital |
2021-12-15 |
| Depixus–SEVERAL: investment, 202112 financing round Series A €30.6m co-led by Lansdowne Partners + PSIM Fund (Bpifrance) |
2021-12-15 |
| Lonza–Agilent: analytical instruments, 202112– strategic alliance to integrate analytical technologies in Cocoon cell therapy production platform |
2021-12-15 |
| Biogazelle–CellCarta: investment, 202112 acquisition of Biogazelle by CellCarta |
2021-12-14 |
| BMS–Immatics: TCR Bispecific, 202112– license ww excl $150m upfront + $770m milestones + royalties to IMA401 programme |
2021-12-14 |
| Ryvu Therapeutics–LifeSci: public relations, 202112 service existent IR by LifeSci Advisors |
2021-12-14 |
| Sirius Medical–SEVERAL: investment, 202112 financing round Series A 2nd closing €na with BOM Brabant Ventures + Holland Capital et al |
2021-12-14 |
| Vifor Pharma–CSL: investment, 202112– cash tender offer CHF10.9b ($11.7b) at CHF167/share ANNOUNCED |
2021-12-14 |
| Arena Pharmaceuticals–Pfizer: investment, 202112– acquisition $6.7b in cash at $100/share by Pfizer ANNOUNCED |
2021-12-13 |
| deepCDR Biologics–Alloy Therapeutics: investment, 202112 acquisition of deepCDR Biologics by Alloy |
2021-12-09 |
| Forbion European Acquisition Corporation–SEVERAL: investment, 202112 SPAC US IPO $110m with 11m units at $10/unit |
2021-12-09 |
| Aleph Farms–Wacker: cell culture media, 202112– collab developm production process for growth-medium proteins for cultured meat |
2021-12-08 |
| Merck (DE)–Merck (DE): investment, 202112 third increase of financial commitment by €600m in evergreen corporate venture fund M Ventures |
2021-12-08 |
| Adendra Therapeutics–Apple Tree Partners: investment, 202112 founding Series A investment Ł40m from ATP Life Sciences UK |
2021-12-07 |
| Emergence Therapeutics–SEVERAL: investment, 202112 financing round Series A €87m led by Pontifax Venture Capital |
2021-12-07 |
| Freenome–HBM: investment, 202112 financing round Series D totalling $300m incl new + co-investor HBM Healthcare Investments |
2021-12-07 |
| Freenome–Novartis: investment, 202112 financing round Series D totalling $300m incl existing + co-investor Novartis |
2021-12-07 |
| Freenome–Perceptive Advisors: investment, 202112 financing round Series D totalling $300m incl co-lead investor Perceptive Advisors |
2021-12-07 |
| Freenome–RA Capital: investment, 202112 financing round Series D totalling $300m incl existing + co-lead investor RA Capital Management |
2021-12-07 |
| Freenome–Roche: investment, 202112 financing round Series D totalling $300m incl existing + co-investor Roche Venture Fund |
2021-12-07 |
| Freenome–SEVERAL: investment, 202112 financing round Series D $300m co-led by Perceptive Advisors + RA Capital Management |
2021-12-07 |
| Freenome–Siemens: breast cancer diagnostics, 202112– collab research using imaging + multi-omics to identify markers for early detection |
2021-12-07 |
| Odyssey Therapeutics–HBM: investment, 202112 financing round Series A totalling $218m incl co-investor HBM Healthcare Investments |
2021-12-07 |
| Odyssey Therapeutics–OrbiMed: investment, 202112 financing round Series A totalling $218m incl lead investor OrbiMed Advisors |
2021-12-07 |
| Odyssey Therapeutics–SEVERAL: investment, 202112 financing round Series A $218m led by OrbiMed Advisors + co-led by SR One |
2021-12-07 |
| Odyssey Therapeutics–SR One: investment, 202112 financing round Series A totalling $218m incl co-lead investor SR One Capital Management |
2021-12-07 |
| Quay Pharmaceuticals–SGS: investment, 202112 acquisition of Quay Pharma by SGS |
2021-12-07 |
| Roche–Recursion Pharmaceuticals: AI-based drug discovery, 202112– strategic collab $150m upfront up to 40 programs to be selected by Roche+Genentech |
2021-12-07 |
| Bayer–Recursion Pharmaceuticals: AI-based drug discovery, 202112– strategic collab expansion to include inferential search capabilities |
2021-12-06 |
| AviadoBio–SEVERAL: investment, 202112 financing round Series A Ł58.6m led by NEA + co-led by Monograph Capital |
2021-12-03 |
| EUSA Pharma–Recordati: investment, 202112– acquisition €750m of EUSA Pharma UK Ltd from EW Healthcare Partners |
2021-12-03 |
| Integra Therapeutics–SEVERAL: investment, 202112 seed financing round €4.5m with Advent FB + Invivo Capital + Takeda Ventures |
2021-12-02 |
| Integra Therapeutics–Takeda: investment, 202112 seed financing round totalling €4.5m incl investor Takeda Ventures |
2021-12-02 |
| Novartis–UCB: Parkinson drugs, 202112– collab up to $1.5b with $150m upfront ww developm + commercialisation of UCB0599 + option for UCB7853 |
2021-12-02 |
| Sixfold Bioscience–SEVERAL: investment, 202112 seed financing round 2nd closing $2.2m bringing total of dilutive + non-elutive funding to $10.5m |
2021-12-02 |
| SciRhom–SEVERAL: investment, 202111 seed financing round extension €8m bringing total funding to €16m |
2021-11-30 |
| Ablaze Pharmaceuticals–RayzeBio: radiopharmaceuticals, 202111c– license excl developm + commercialisation to series of products in Greater China |
2021-11-29 |
| Ablaze Pharmaceuticals–SEVERAL: investment, 202111 financing round Series A $75m co-led by Vivo Capital + AdvanTech Capital |
2021-11-29 |
| HotSpot Therapeutics–Life Sciences Partners: investment, 202111 financing round Series C totalling $100m incl new + significant co-investor LSP |
2021-11-29 |
| HotSpot Therapeutics–SEVERAL: investment, 202111 financing round Series C $100m led by Pivotal BioVenture Partners |
2021-11-29 |
| HotSpot Therapeutics–Sofinnova: investment, 202111 financing round Series C totalling $100m incl existing + co-investor Sofinnova Partners |
2021-11-29 |
| Lengo Therapeutics–Blueprint Medicines: investment, 202111– acquisition $250m cash upfront + $215m milestones SIGNED |
2021-11-29 |
| Quell Therapeutics–SEVERAL: investment, 202111 financing round Series B $156m co-led by Jeito + Ridgeback Capital + SV Health Investors + Fidelity |
2021-11-29 |
| Allorion Therapeutics–Qiming: investment, 202111 financing round Series A totalling $40m incl lead investor Qiming Venture Partners |
2021-11-24 |
| Allorion Therapeutics–SEVERAL: investment, 202111 financing round Series A $40m led by Qiming Venture Partners |
2021-11-24 |
| Relief Therapeutics–BioXcel: AI-based drug discovery, 202111– strategic collab €na using AlphaMeld platform of InveniAI for drug discovery |
2021-11-24 |
| BeiGene–SEVERAL: investment, 202111– China mainland IPO in Renminbi with 115m+17.26m RMB shares on START Market of Shanghai Stock Exchange |
2021-11-23 |
| Nykode–Regeneron: investment, 202111 equity investment $20m at a premium of 20% as part of license + collab agreement |
2021-11-23 |
| Regeneron–Nykode: therapeutic vaccines, 202111– collab + license agreem $30m upfront + $875m milestones off-the-shelf vaccines for cancer + infections |
2021-11-23 |
| Abveris–Twist Bioscience: investment, 202111– acquisition merger $150m in shares with max $10m cash at closing + $40m milestones in shares |
2021-11-22 |
| Molecubes–Bruker: investment, 202111 acquisition €na by Bruker |
2021-11-19 |
| Axel Semrau–Trajan: investment, 202111 acquisition €19.85m by Trajan Group |
2021-11-18 |
| Dicerna Pharmaceuticals–Novo Group: investment, 202111– cash tender offer $38.25/share representing total equity value of $3.3b ANNOUNCED |
2021-11-18 |
| Owkin–Sanofi: investment, 202111 equity investment $180m by Sanofi in connection with strategic collaboration |
2021-11-18 |
| Sanofi–Owkin: cancer drug RnD, 202111– strategic collaboration with $90m for three years + milestones |
2021-11-18 |
| Synthace–Horizon Ventures: investment, 202111 financing round Series C totalling $35m incl existing + co-lead investor Horizon Ventures |
2021-11-16 |
| Synthace–SEVERAL: investment, 202111 financing round Series C $35m co-led by Sofinnova Partners + Horizon Ventures |
2021-11-16 |
| Synthace–Sofinnova: investment, 202111 financing round Series C totalling $35m incl existing + co-lead investor Sofinnova Partners |
2021-11-16 |
| Bruker–Bico: MS-based single cell proteomics, 202111– co-marketing of Cellenion’s cellenONE with timsTOF SCP mass spectrometers |
2021-11-15 |
| Thermo Fisher–Bico: MS-based single cell proteomics, 202111– co-marketing Cellenion’s cellenONE + proteoCHIP with Orbitrap MS systems + TMT technology |
2021-11-15 |
![[LSUS] Life-Sciences-USA.com - The Transatlantic Life Sciences Web Portal](/images/basics/lsus-life-sciences-usa-portal-logo-2019.png){kind=logo}
Date![Picture [iito] No Content Marketing 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-no-content-marketing.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
